Back to Search
Start Over
Examination of protective and therapeutic effects of ruscogenin on cerulein-induced experimental acute pancreatitis in rats
- Source :
- Annals of Surgical Treatment and Research
- Publication Year :
- 2019
-
Abstract
- WOS:000500944000001 PubMed ID: 31824881 Purpose: To determine the potential protective and therapeutic effects and action mechanism of ruscogenin on cerulein-induced acute pancreatitis (AP) model in rats. Methods: Overall, 32 rats were attenuated to the sham (2-mL/kg/day isotonic solution for 4 weeks), control (20-mu g/kg cerulein-induced AP for 12 hours), prophylaxis groups (cerulein-induced AP following 3-mL/kg/day ruscogenin for 4 weeks) and treatment (3-mL/kg/day ruscogenin following cerulein-induced AP for 12 hours). Blood samples were collected for biochemical analysis of nitric oxide synthase 1 (NOS1/neuronal NOS), malondialdehyde (MDA) and intercellular adhesion molecule 1 (ICAM-1). After sacrification, pancreas tissues were collected and prepared for light microscopic (hematoxylin and eosin), immunohistochemical (nuclear factor kappa B) and biochemical analysis (tumor necrosis factor-alpha [TNF-alpha], interleukin-6 and 1 beta [IL-6 and IL-1 beta], CRP, high-sensitivity CRP [hs-CRP] amylase, lipase, and ICAM-1). Ultrastructural analysis was performed by transmission electron microscopy. Results: The protective and therapeutic actions of ruscogenin were accomplished by improvements in histopathology, by decreasing blood cytokine levels of CRP, hs-CRP levels, TNF-alpha, IL-6, IL-1 beta, ICAM-1, by reducing the pancreatic enzymes amylase and lipase in blood, and by suppressing the expression of nuclear factor kappa B, ICAM-1, and NOS-1, but not MDA in pancreatic tissues. Ruscogenin also improved cerulein-induced ultrastructural degenerations in endocrine and exocrine cells, especially in treatment group. Conclusion: The present findings have demonstrated the beneficial protective and therapeutical effects of ruscogenin, nominating it as a highly promising supplementary agent to be considered in the treatment of AP, and even as a protective agent against the damages induced by disease. Research and Development Expenses Account under Circulating Capital Budget of University of Health Science Bagcilar Training and Research Hospital [2016/24] The present project was supported by Research and Development Expenses Account under Circulating Capital Budget of University of Health Science Bagcilar Training and Research Hospital (Project No: 2016/24). Authors thank to Assoc. Prof. Ilknur Dag from Central Research Laboratory Application and Research Center of Eskisehir Osmangazi University, Turkey, for the analysis by transmission electron microscopy.
- Subjects :
- MECHANISM
medicine.medical_specialty
medicine.medical_treatment
MODELS
H&E stain
Pharmacology
ADHESION
03 medical and health sciences
chemistry.chemical_compound
0302 clinical medicine
INFLAMMATION
ACINAR
medicine
INJURY
Pancreas
Ceruletide
RESVERATROL
Ruscogenin
business.industry
NF-kappa B
Malondialdehyde
medicine.disease
Cytokine
medicine.anatomical_structure
chemistry
Pancreatitis
030220 oncology & carcinogenesis
Acute pancreatitis
030211 gastroenterology & hepatology
Surgery
Histopathology
Original Article
business
Subjects
Details
- ISSN :
- 22886575
- Volume :
- 97
- Issue :
- 6
- Database :
- OpenAIRE
- Journal :
- Annals of surgical treatment and research
- Accession number :
- edsair.doi.dedup.....a7180063faa63ecc3cc8c2a0c157981f